Ga-68-DOTATATE and F-18-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival Region
CLINICAL NUCLEAR MEDICINE
Authors: Dadgar, Habibollah; Norouzbeigi, Nasim; Ahmadzadehfar, Hojjat; Assadi, Majid
Abstract
We present a 48-year-old woman with an olfactory neuroblastoma who was referred for accurate staging using PET/CT. The Ga-68-DOTATATE PET/CT showed a 51 x 32-mm mass with an SUVmax of 7.59 in the sphenoidal sinuses, whereas radiotracer uptake on F-18-FDG PET/CT was similar to that of brain tissue. Ga-68-DOTATATE PET/CT might be especially useful in regions with difficult tumor visualization resulting from high background, such as brain tissue. The results of this case may suggest that somatostatin receptor imaging in patients with esthesioneuroblastoma may facilitate the potential application of radiotheranostic agents for the treatment of this aggressive subtype of tumors.
Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Authors: Kecskes, Angela; Pohoczky, Krisztina; Kecskes, Miklos; Varga, Zoltan V.; Kormos, Viktoria; Szoke, Eva; Henn-Mike, Nora; Feher, Mate; Kun, Jozsef; Gyenesei, Attila; Renner, Eva; Palkovits, Miklos; Ferdinandy, Peter; Abraham, Istvan M.; Gaszner, Balazs; Helyes, Zsuzsanna
Abstract
Somatostatin is an important mood and pain-regulating neuropeptide, which exerts analgesic, anti-inflammatory, and antidepressant effects via its Gi protein-coupled receptor subtype 4 (SST4) without endocrine actions. SST4 is suggested to be a unique novel drug target for chronic neuropathic pain, and depression, as a common comorbidity. However, its neuronal expression and cellular mechanism are poorly understood. Therefore, our goals were (i) to elucidate the expression pattern of Sstr4/SSTR4 mRNA, (ii) to characterize neurochemically, and (iii) electrophysiologically the Sstr4/SSTR4-expressing neuronal populations in the mouse and human brains. Here, we describe SST4 expression pattern in the nuclei of the mouse nociceptive and anti-nociceptive pathways as well as in human brain regions, and provide neurochemical and electrophysiological characterization of the SST4-expressing neurons. Intense or moderate SST4 expression was demonstrated predominantly in glutamatergic neurons in the major components of the pain matrix mostly also involved in mood regulation. The SST4 agonist J-2156 significantly decreased the firing rate of layer V pyramidal neurons by augmenting the depolarization-activated, non-inactivating K+ current (M-current) leading to remarkable inhibition. These are the first translational results explaining the mechanisms of action of SST4 agonists as novel analgesic and antidepressant candidates.
COA
Publication 
Loading ......
